Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib

Clinical Lymphoma and Myeloma

Volumn 9, Issue 2, 2009, Pages 151-153

  Pour, Ludek ^a,b   Adam, Zdenek ^a,b   Buresova, Lucie ^b   Krejci, Marta ^a   Krivanova, Andrea ^a   Sandecka, Viera ^a,b   Zahradova, Lenka ^a,b   Buchler, Tomas ^c   Vorlicek, Jiri ^a   Hajek, Roman ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c FAKULTNÍ THOMAYEROVA NEMOCNICE   (Czech Republic)

Author keywords

Dermatomal rash; Herpes zoster; Herpetic neuralgia; Infectious complications

Indexed keywords

ACICLOVIR; BORTEZOMIB; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HERPES ZOSTER; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PROPHYLAXIS; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION; DRUG EFFECT; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY; VIROLOGY; VIRUS ACTIVATION;

ACYCLOVIR; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BORONIC ACIDS; FEMALE; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROSPECTIVE STUDIES; PYRAZINES; VIRUS ACTIVATION;

EID: 67650692800     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.036     Document Type: Article

References (16)

1. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487-98.
2. Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006; 91:1498-505.
3. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129:776-83.
4. Gladney SP, Lonial S, Kaufman JL. Multiple myeloma presenting with advanced renal failure: a case report and new treatment options. Clin Lymphoma Myeloma 2008; 8:52-4.
5. Adam Z, Hajek R, Mayer J, et al. Multiple Myeloma and Other Monoclonal Gammapathies. Masaryk University: Brno, 1999, 325.
6. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007; 25:3892-901.
7. Spicka I, Hajek R, Vytrasova M. Bortezomib (Velcade) in relapsed/refractory multiple myeloma the first experience in the Czech Republic. [in Czech]. Cas Lek Cesk 2005; 144:636, 638-40.
8. Chanan-Khan A, Sonneveld P, Schuster MW, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008; 26:4784-90.
9. Maisnar V, Radocha J, B̈chler T, et al. Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment. Eur J Haematol 2007; 79:305-9.
10. Zemanova M, Scudla V, Adam Z, et al. Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma. Neoplasma 2008; 55:345-9.
11. Kropff M, Bisping G, Schuck E, et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol 2007; 138:330-7.
12. Tong Y, Qian J, Li Y, et al. The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients. Am J Hematol 2007; 82:403-4.
13. San Miguel JF, Schlag R, Khuageva N. MMY-3002: A phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma. Blood 2007; 110:31a (Abstract 76).
14. Hussein MA. Management of toxicities from novel agents. Haematologica 2007; 92(suppl 2): (Abstract S5.6).
15. Wareham DW, Breuer J. Herpes zoster. BMJ 2007; 334:1211-5.
16. Ludwig H, Adam Z, Hajek R, et al. Recovery of renal impairment by bortezomib-doxorubicin-dexamethasone (BDD) in multiple myeloma (MM) patients with acute renal failure. Results from an ongoing phase II study. Blood 2007; 110:1054a (Abstract 3603).